Hebei Wutu Pharmaceutical Co. Ltd. has synthesized transient receptor potential cation channel subfamily V member 4 (TRPV4) antagonists reported to be useful for the treatment of liver cancer, cirrhosis, hepatic fibrosis, chronic hepatitis B and liver failure.
Beijing Danatlas Pharmaceutical Technology Co. Ltd. has disclosed poly(ADP-ribose) glycohydrolase (PARG) inhibitors reported to be useful for the treatment of cancer.
J Ints Bio Co. Ltd. has announced research findings with JIN-001, in development in collaboration with MD Anderson Cancer Center, for the treatment of brain tumors.
Researchers from Cogent Biosciences Inc. have presented data on their PI3KA H1047R mutant inhibitor CGT-6297 PI3KA wild-type inhibitors can lead to toxicity issues such as hyperglycemia, gastrointestinal toxicity and skin reactions.
Researchers from KU Leuven presented novel urokinase plasminogen activator receptor-associated protein (uPARAP)-targeted antibody-drug conjugates (ADC), ADCE-017 and ADCE-202, being developed for the treatment of soft tissue sarcoma.
Hemogenyx Pharmaceuticals plc has obtained approval by the institutional review board (IRB) of the company’s first clinical site to initiate a phase I trial of the company’s lead asset, HEMO-CAR-T, for the treatment of relapsed or refractory acute myeloid leukemia (AML) in adults.
Oncobone Ventures Ltd. and Origenis GmbH have signed a framework agreement to develop novel therapies targeting cancer bone metastasis. Origenis leverages its artificial intelligence (AI)-driven technology platform Molmind-Moresystem-Brainstorm to design innovative targeted small-molecule therapies.
Researchers from Caedo Oncology AS presented the discovery and preclinical characterization of CO-005, a novel anti-CD47 fusion protein being developed for the treatment of lymphoma.
Adcendo ApS has closed an oversubscribed $135 million series B financing round to support its development of first-in-class antibody-drug conjugates (ADCs) for the treatment of cancers with a high unmet medical need.
RSS
